Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019

[1]  Jisoo A. Kwon,et al.  Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. , 2023, The lancet. Gastroenterology & hepatology.

[2]  R. Baggaley,et al.  Prevention and treatment of infectious diseases in migrants in Europe in the era of universal health coverage. , 2022, The Lancet. Public health.

[3]  Lalu Muhammad Irham,et al.  Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2022, The lancet. Gastroenterology & hepatology.

[4]  Jisoo A. Kwon,et al.  Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. , 2022, The lancet. Gastroenterology & hepatology.

[5]  H. Janssen,et al.  The impact of the first, second and third waves of covid‐19 on hepatitis B and C testing in Ontario, Canada , 2021, Journal of viral hepatitis.

[6]  D. Roccatello,et al.  A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy , 2021, Viruses.

[7]  Z. Younossi,et al.  Causes of Death in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease and Chronic Viral Hepatitis B and C. , 2021, Annals of hepatology.

[8]  J. Crespo,et al.  HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination? , 2021, Journal of Hepatology.

[9]  M. Buti,et al.  Impact of the COVID-19 pandemic on HCV elimination in Spain , 2020, Journal of Hepatology.

[10]  G. Jeffrey,et al.  Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles , 2020, Frontiers in Cellular and Infection Microbiology.

[11]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[12]  Jacob L. Stubbs,et al.  Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 , 2020, The Lancet.

[13]  J. Lazarus,et al.  A global investment framework for the elimination of hepatitis B , 2020, Journal of Hepatology.

[14]  J. Pawlotsky,et al.  EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.

[15]  J. Lazarus,et al.  Global hepatitis C elimination: an investment framework. , 2020, The lancet. Gastroenterology & hepatology.

[16]  J. Lazarus,et al.  Progress towards elimination goals for viral hepatitis , 2020, Nature Reviews Gastroenterology & Hepatology.

[17]  I. Waked,et al.  Screening and Treatment Program to Eliminate Hepatitis C in Egypt. , 2020, The New England journal of medicine.

[18]  M. Alavi,et al.  Global elimination of hepatitis C virus by 2030: why not? , 2020, Nature Medicine.

[19]  M. Alavi,et al.  Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. , 2019, Journal of hepatology.

[20]  G. Cesana,et al.  Systematic review: economic evaluations of HCV screening in the direct‐acting antivirals era , 2019, Alimentary pharmacology & therapeutics.

[21]  J. Ward,et al.  The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals , 2019, Journal of virus eradication.

[22]  J. Lazarus,et al.  Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. , 2018, Journal of hepatology.

[23]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[24]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[25]  Mathieu Laversanne,et al.  International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007 , 2016, International journal of cancer.

[26]  L. Gallagher.  Hepatitis B. , 2016, Journal.

[27]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[28]  L. Serfaty.  Clinical Implications of Concomitant Alcohol Use, Obesity, and Viral Hepatitis. , 2016, Gastroenterology.

[29]  M. Stepanova,et al.  Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. , 2016, Gastroenterology.

[30]  Mirjam Kretzschmar,et al.  Disability weights for the Global Burden of Disease 2013 study. , 2015, The Lancet. Global health.

[31]  R. Mikolajczyk,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[32]  G. Signoriello,et al.  Clinical and virological characteristics associated with severe acute hepatitis B. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  Rafael Lozano,et al.  Modeling causes of death: an integrated approach using CODEm , 2012, Population Health Metrics.

[34]  A J Hall,et al.  The influence of age on the development of the hepatitis B carrier state , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[35]  Edinburgh Research Explorer Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement , 2022 .